Survodutide (10mg Vial) Dosage Protocol
Investigational dual GLP-1/glucagon receptor agonist (BI 456906) — not approved; in Phase 3 for obesity and MASH.
Pre-filled with this protocol’s recommended BAC water and documented starting dose — edit any field to run your own numbers. Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Full reconstitution guide → · Advanced calculator →Mix & measure Survodutide · 10 mg
Dosing & Reconstitution Guide
A single practical dilution with accurate once-weekly dosing, step by step
Standard / Gradual Approach (2.0 mL = ~5.0 mg/mL)
Reconstitute: Add 2.0 mL bacteriostatic water to one 10 mg vial → final concentration ~5.0 mg/mL (5,000 mcg/mL).
Typical weekly range: 600–4800 mcg once weekly, raised gradually over a 16–24 week escalation.
Easy measuring: At ~5.0 mg/mL, 1 unit = 0.01 mL = 50 mcg on a U-100 syringe. Each weekly dose in micrograms divided by 50 gives the number of units.
Storage: Lyophilized: store at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F), protect from light and avoid freeze–thaw of the mixed solution.
Why Survodutide draws research interest
These are the directions researchers and the peptide community most often explore Survodutide for — so you know you’re in the right place. They describe what is being studied, not proven benefits, approved uses, or promised results.
Weight loss & obesity
The primary reason people look it up: investigated in Phase 3 research on obesity as an unapproved dual GLP-1/glucagon agonist.
MASH & liver fibrosis
Studied in Phase 3 research on metabolic dysfunction-associated steatohepatitis (MASH); investigational, not approved for any use.
Appetite & food intake
Explored in research on how GLP-1 receptor signaling influences appetite and food intake; findings are preclinical and clinical-trial only.
Fat metabolism & energy expenditure
Researched for the glucagon-receptor arm's role in fat metabolism and energy expenditure; investigational compound, results not established.
Evidence ranges from early laboratory work to clinical trials depending on the use — the sections below cover the actual data and sources.
Quickstart Highlights
Survodutide (BI 456906) is an investigational dual GLP-1 receptor / glucagon receptor agonist developed by Boehringer Ingelheim and Zealand Pharma for obesity and metabolic dysfunction-associated steatohepatitis (MASH)[1]. In clinical trials it is given as a once-weekly subcutaneous injection titrated upward over roughly 20 weeks. It is not approved by the FDA or EMA; it holds FDA Breakthrough Therapy Designation (2024) for non-cirrhotic MASH with fibrosis — an expedited-development status, not an approval — and is in Phase 3 trials. Presented for research and educational use only.
Add 2.0 mL bacteriostatic water to one 10 mg vial → ~5.0 mg/mL (5,000 mcg/mL). The 2.0 mL volume keeps higher weekly doses at or below 1.0 mL per injection.
600–4800 mcg once weekly, titrated upward gradually across a 16–24 week escalation anchored to clinical-trial ranges.
At ~5.0 mg/mL, 1 unit = 0.01 mL = 50 mcg on a U-100 syringe; 600 mcg = 12 units and 4800 mcg = 96 units.
Lyophilized: store at −20 °C (−4 °F); once reconstituted, refrigerate at 2–8 °C (35.6–46.4 °F), protect from light and avoid freeze–thaw.
Important: Start with the Prep & Injection Guide — it covers the preparation and safety basics every protocol on this site assumes.
Frequency: one subcutaneous injection once weekly, titrating up as tolerated. The doses above are weekly per-injection amounts, not daily — this regimen is once weekly. Clinical trials escalated the weekly dose over roughly 20 weeks before maintenance; slower escalation can reduce gastrointestinal side effects such as nausea and diarrhea[2][3].
Reconstitution Steps
Draw 2.0 mL of bacteriostatic water into a sterile syringe.
Release it slowly down the vial’s inner wall to limit foaming.
Swirl or roll gently until fully dissolved — don’t shake.
Label with the date and concentration, then refrigerate at 2–8 °C (35.6–46.4 °F), shielded from light.
The 2.0 mL dilution is chosen so even the highest weekly doses stay at or below 1.0 mL per injection while keeping unit math simple. Avoid freezing the reconstituted solution, since freeze–thaw can denature the peptide.
Supplies Needed
Quantities below assume an 8–16 week course of once-weekly injections with gradual titration, anchored to clinical-trial dose ranges.
Totals are cumulative across the titration phases at one once-weekly dose per week.
- 8 weeks (0.6→1.2 mg): total ≈ 7.2 mg → 1 vial
- 12 weeks (adds 1.8 mg phase): total ≈ 14.4 mg → 2 vials
- 16 weeks (adds 2.4 mg phase): total ≈ 24.0 mg → 3 vials
- Per week: 1 syringe (1 injection/week)
- 8 weeks: 8 syringes
- 12 weeks: 12 syringes
- 16 weeks: 16 syringes
Use ~2.0 mL per 10 mg vial for reconstitution.
- 8 weeks (1 vial): 2.0 mL → 1 bottle
- 12 weeks (2 vials): 4.0 mL → 1 bottle
- 16 weeks (3 vials): 6.0 mL → 1 bottle
One for the vial stopper + one for the injection site each dose.
- Per week: 2 swabs
- 8 weeks: 16 swabs → 1 box
- 16 weeks: 32 swabs → 1 box
Protocol Overview
A concise summary of the once-weekly regimen, anchored to dose ranges used in Survodutide clinical trials.
- ▪Goal: Investigational dual GLP-1 / glucagon receptor activation studied for weight reduction and improvement of hepatic steatosis (MASH) — effects observed in clinical trials, not an approved indication[1].
- ▪Schedule: Once-weekly subcutaneous injections with stepwise escalation across roughly 16–24 weeks before maintenance.
- ▪Dose Range: 600–4800 mcg weekly (0.6–4.8 mg), escalating as tolerated within trial-tested ranges[2].
- ▪Reconstitution: 2.0 mL bacteriostatic water per 10 mg vial gives ~5.0 mg/mL, keeping higher weekly doses at or below 1.0 mL.
- ▪Storage: Keep the dry vial frozen at −20 °C (−4 °F); once mixed, refrigerate at 2–8 °C, protect from light and avoid freeze–thaw.
Dosing Protocol
A suggested once-weekly titration approach informed by Survodutide clinical studies.
- ▪Start: Begin at 600 mcg once weekly to gauge tolerability.
- ▪Titrate: Increase by roughly 600 mcg every 4 weeks as tolerated (0.6 → 1.2 → 1.8 → 2.4 mg; optional 3.6 → 4.8 mg), mirroring the escalation used in trials[2][3].
- ▪Frequency: Once per week, subcutaneously.
- ▪Timing: Use a consistent weekly day and time, and rotate injection sites systematically.
- ▪Note: Slower escalation can mitigate GI adverse events such as nausea and diarrhea.
Storage Instructions
Correct storage is what preserves the peptide’s stability and activity.
- ▪Lyophilized: Hold the dry vial at −20 °C (−4 °F) in dry, dark conditions and limit moisture exposure[6].
- ▪Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F), protect from light and use within about 28 days; do not freeze the mixed solution, as freezing can denature peptides[7].
- ▪Handling: Let frozen vials warm to room temperature before opening so condensation won’t form, and keep the solution clear of heat and direct light.
- ▪Freeze–thaw: Avoid repeated freeze–thaw cycles of the reconstituted solution.
Important Notes
Practical points that keep weekly administration safe and consistent.
- ▪Sterile technique: Use a fresh sterile U-100 insulin syringe each time and drop it straight into a puncture-proof sharps container afterward.
- ▪Site rotation: Move between abdomen, thighs and upper arms to reduce local irritation and lipohypertrophy[8].
- ▪Slow injection: Push the plunger slowly and pause a few seconds before withdrawing the needle to prevent backflow; do not aspirate for subcutaneous injections.
- ▪Manage GI effects: Nausea and diarrhea are the most common adverse events; a slower escalation and smaller, more frequent meals can help.
- ▪Regulatory note: Survodutide is not FDA- or EMA-approved for human use; it is investigational and presented here for research and educational purposes only.
How This Works
Survodutide (BI 456906) is an investigational dual agonist that activates both the GLP-1 receptor and the glucagon receptor, co-developed by Boehringer Ingelheim and Zealand Pharma[1].
GLP-1 receptor activation reduces appetite and slows gastric emptying, while glucagon receptor agonism is thought to raise energy expenditure and act on the liver to reduce hepatic fat (steatosis). Engaging both pathways is the rationale for studying it in obesity and in metabolic dysfunction-associated steatohepatitis (MASH)[4].
Phase 2 trials in obesity used once-weekly subcutaneous dosing with dose-dependent weight loss, and a Phase 2 MASH trial reported improvement in liver disease[2][5]. Phase 3 development is ongoing — SYNCHRONIZE in obesity and LIVERAGE in MASH.
Important caveat: Survodutide is not approved by the FDA or EMA. It holds FDA Breakthrough Therapy Designation (September 2024) for non-cirrhotic MASH with moderate-to-advanced fibrosis — an expedited-development status, not an approval. It remains investigational and is presented here for research and educational purposes only.
Lifestyle Factors
Habits that may support metabolic outcomes alongside the protocol.
- ▪Nutrition: Adopt a balanced, calorie-appropriate diet emphasizing protein and whole foods.
- ▪Activity: Combine resistance and aerobic training to reinforce metabolic adaptations and help preserve lean mass.
- ▪Sleep: Aim for 7–9 hours to support appetite regulation and overall metabolic health.
- ▪Hydration & adherence: Stay well hydrated and keep injections on a consistent weekly schedule to support tolerability.
Potential Benefits & Side Effects
Findings reported in Survodutide clinical trials; it remains investigational and individual results vary.
Potential Benefits
- ▪Weight reduction (clinical): Dose-dependent weight loss reported in Phase 2 obesity trials over a ~20-week escalation[2].
- ▪Liver outcomes (clinical): Phase 2 MASH data showed improvement in liver disease versus placebo[5].
- ▪Regulatory recognition: FDA Breakthrough Therapy Designation (2024) for non-cirrhotic MASH with fibrosis — an expedited status, not an approval[3].
- ▪Note on status: Survodutide is not approved and is still in Phase 3 trials; outcomes are not established for general use.
Common Side Effects
- ▪Gastrointestinal: Nausea, diarrhea and vomiting are the most common adverse events, typically dose-related and often easing with slower escalation.
- ▪Injection-site reactions: Mild redness or tenderness can occur; rotating sites helps.
- ▪Investigational profile: Long-term safety is still being characterized in ongoing Phase 3 trials.
Injection Technique
General subcutaneous technique, following established clinical best-practice guidance[9][10].
Pre-Injection Preparation
- ▪Wash your hands well with soap and water.
- ▪Wipe the vial stopper with an alcohol swab and let it air-dry.
- ▪Choose a site (abdomen, thigh, or upper arm) and clean it with a fresh alcohol swab, letting it dry fully[10].
- ▪Draw the intended weekly dose, then check for air bubbles and push any out.
Injection Procedure
- ▪Pinch a skinfold at the chosen site between thumb and forefinger.
- ▪Insert the needle into the pinch at a 45–90-degree angle (use 45 degrees if the fat layer is thin)[9].
- ▪Skip aspiration for subcutaneous shots — it isn’t needed[9].
- ▪Press the plunger slowly and steadily until it’s fully down.
- ▪Wait 5–10 seconds, then pull the needle straight out to prevent leakage.
Post-Injection Care
- ▪Drop the used syringe straight into a puncture-proof sharps container — never recap a needle.
- ▪Return the reconstituted vial to the fridge right away.
- ▪Rotate the injection site each week to prevent irritation and lipohypertrophy[8].
- ▪Watch the site for excess redness, swelling, or signs of infection.
Recommended Source
For high-purity research peptides, we point researchers to Prime Lab Peptides.
Why Prime Lab Peptides?
- ▪Top-rated on Trustpilot: Independently reviewed as the highest-rated peptide lab on Trustpilot — making it the best current source in the USA.
- ▪Third-party tested: Every batch ships with a Certificate of Analysis (COA) confirming purity and composition.
- ▪Consistent quality: ISO-aligned manufacturing and handling keep product integrity reliable batch to batch.
- ▪Cold-chain integrity: Temperature-controlled shipping and storage across the whole fulfilment chain.
- ▪Research-grade purity: Fit for educational and research use that demands high-quality peptides.
Note: Survodutide is investigational and may not be offered by every supplier. Product availability and specifications are subject to change — verify current product details on the supplier website.
References
- 1
New England Journal of MedicineSurvodutide (BI 456906), a dual glucagon/GLP-1 receptor agonist: Phase 2 trial in people with overweight or obesity.
- 2
The Lancet Diabetes & EndocrinologyDose-finding Phase 2 study of survodutide with once-weekly subcutaneous dosing and dose-dependent weight loss.
- 3
U.S. Food & Drug AdministrationBreakthrough Therapy Designation for survodutide in non-cirrhotic MASH with moderate-to-advanced fibrosis (an expedited-development status, not an approval).
- 4
Molecular Metabolism (PubMed)Pharmacology of dual GLP-1/glucagon receptor agonism: appetite reduction, energy expenditure and hepatic fat.
- 5
New England Journal of MedicinePhase 2 trial of survodutide in metabolic dysfunction-associated steatohepatitis (MASH) showing improvement versus placebo.
- 6
Peptide Storage GuideBest practices for storing lyophilized peptides (temperature, humidity and light protection).
- 7
Bacteriostatic Water GuidanceBacteriostatic water for injection: multi-dose vial stability and handling.
- 8
NCBI BookshelfBest practices for subcutaneous injection: aseptic technique and site rotation.
- 9
Centers for Disease Control and Prevention (CDC)Subcutaneous injection technique: angle, site and no-aspiration guidance.
- 10
Subcutaneous Injection Technique (Patient Education)How to administer a subcutaneous injection: clinical technique guidelines.
- 11
ClinicalTrials.govSurvodutide Phase 3 program registry entries (SYNCHRONIZE in obesity; LIVERAGE in MASH).
Survodutide — frequently asked questions
How do I reconstitute a 10 mg vial of Survodutide?
Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units.
How much bacteriostatic water should I add to Survodutide?
There is no single correct amount — more water simply spreads the same 10 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units.
What do the "units" on an insulin syringe mean?
On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand.
How should I store Survodutide after mixing?
Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product.
How many doses does a 10 mg vial of Survodutide provide?
Divide the vial strength of 10 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose.
Is Survodutide approved for human use?
No. Survodutide is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.
New protocols & dosing updates
Reconstitution charts, new peptide protocols and safety updates — straight to your inbox. No spam, unsubscribe anytime.